Table 1 Demographic, clinical, laboratory, and microbiologic data of the 270 adult patients with teicoplanin-treated MRSA BSIs
Parameter | No. (%) |
|---|---|
Age (years) (mean ± SD) | 71.3 ± 16.3 |
Gender (male/female) | 197 (73.0%)/73 (27.0%) |
Charlson comorbidity index (mean ± SD) | 4.2 ± 2.3 |
Primary focus of bacteremia | |
Urinary tract | 12 (3.8%) |
Respiratory tract | 99 (31.0%) |
Surgical wound | 21 (6.6%) |
Skin | 35 (11.0%) |
Intra-abdominal | 7 (2.2%) |
Intravenous catheter | 94 (29.5%) |
No obvious focus | 51 (16.0%) |
Location of onset | |
ICU | 110 (40.7%) |
General ward | 157 (58.1%) |
Community | 3 (1.1%) |
Deep-seated abscess or osteomyelitis | 65 (24.1%) |
Infective endocarditis | 32 (11.9%) |
Septic shock at onset | |
Yes | 37 (13.7%) |
No | 233 (86.3%) |
Cardiovascular diseases | |
Yes | 199 (73.7%) |
No | 71 (26.3%) |
Respiratory diseases | |
Yes | 68 (25.2%) |
No | 202 (74.8%) |
Neurologic diseases | |
Yes | 86 (31.9%) |
No | 184 (68.2%) |
Gastrointestinal tract diseases | |
Yes | 105 (38.9%) |
No | 165 (61.1%) |
Hepatobiliary tract diseases | |
Yes | 55 (20.4%) |
No | 215 (79.6%) |
Genitourinary tract diseases | |
Yes | 109 (40.4%) |
No | 161 (59.6%) |
Endocrinologic diseases | |
Yes | 112 (41.5%) |
No | 158 (58.5%) |
Malignancies | |
Yes | 98 (36.3%) |
No | 172 (63.7%) |
Autoimmune diseases | |
Yes | 20 (7.4%) |
No | 250 (92.6%) |
Immunosuppression | |
Yes | 81 (30.0%) |
No | 189 (70.0%) |
White blood cell count* | |
< 4,000/μL | 36 (13.4%) |
4,000 – 12,000/μL | 106 (39.3%) |
> 12, 000/μL | 128 (47.4%) |
Anemia* | |
Yes | 158 (58.7%) |
No | 111 (41.3%) |
Thrombocytopenia* | |
Yes | 112 (41.8%) |
No | 156 (58.2%) |
Hypoalbuminemia* | |
Yes | 25 (17.7%) |
No | 116 (82.3%) |
Abnormal liver function test with clinical significance* | |
Yes | 24 (12.8%) |
No | 163 (87.2%) |
CRP (mean ± SD)* | 13.2 ± 32.3 (mg/dL) |
Impaired renal function* | |
Yes | 109 (40.4%) |
No | 161 (59.6%) |
Effective treatment within 48 hours* | |
Yes | 164 (64.5%) |
No | 72 (35.5%) |
Clinical response at the end of teicoplanin therapy | |
Favorable outcome | 171 (63.3%) |
Un-favorable outcome | 99 (36.7%) |
Day 14 all-cause death | 35 (13.0%) |
Day 30 all-cause death | 71 (26.3%) |
MIC of teicoplanin by dilution method* | |
≤1 mg/L | 161 (76.7%) |
2 mg/L | 46 (21.9%) |
4 mg/L | 3 (1.4%) |
MIC of teicoplanin by Etest* | |
≤1 mg/L | 87 (41.4%) |
1.5 mg/L | 86 (41.0%) |
2 mg/L | 32 (15.2%) |
> 2 mg/L | 4 (1.9%) |